Raffles Medical Group Likely Entering Stronger Growth Phase -- Market Talk

Dow Jones

3 hours ago

0318 GMT - Raffles Medical Group is likely entering a stronger growth phase in 2026-2027, RHB Research's Shekhar Jaiswal says in a report. The recovery in its Singapore-based hospitals may extend on specialist-led volumes and supportive insurer-panel flow, while the losses at its China-based clinics could continue to narrow, the analyst says. The Singapore-listed healthcare provider's margins should also remain resilient on measured price increases and tech-driven productivity gains, offsetting wage inflation. RHB Research raises the stock's target price to S$1.30 from S$1.15 to reflect a valuation rollover, with its buy rating unchanged. Shares are 0.9% higher at S$1.08. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

February 23, 2026 22:18 ET (03:18 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613763105"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613763105\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613763105?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613763105","market":"sg","top_or_hot":-1,"title":"Raffles Medical Group Likely Entering Stronger Growth Phase -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0318 GMT - Raffles Medical Group is likely entering a stronger growth phase in 2026-2027, RHB Research's Shekhar Jaiswal says in a report. The recovery in its Singapore-based hospitals may extend on specialist-led volumes and supportive insurer-panel flow, while the losses at its China-based clinics could continue to narrow, the analyst says. The Singapore-listed healthcare provider's margins should also remain resilient on measured price increases and tech-driven productivity gains, offsetting wage inflation. RHB Research raises the stock's target price to S$1.30 from S$1.15 to reflect a valuation rollover, with its buy rating unchanged. Shares are 0.9% higher at S$1.08. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 23, 2026 22:18 ET (03:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raffles Medical Group Likely Entering Stronger Growth Phase -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaffles Medical Group Likely Entering Stronger Growth Phase -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-24 11:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0318 GMT - Raffles Medical Group is likely entering a stronger growth phase in 2026-2027, RHB Research's Shekhar Jaiswal says in a report. The recovery in its Singapore-based hospitals may extend on specialist-led volumes and supportive insurer-panel flow, while the losses at its China-based clinics could continue to narrow, the analyst says. The Singapore-listed healthcare provider's margins should also remain resilient on measured price increases and tech-driven productivity gains, offsetting wage inflation. RHB Research raises the stock's target price to S$1.30 from S$1.15 to reflect a valuation rollover, with its buy rating unchanged. Shares are 0.9% higher at S$1.08. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 23, 2026 22:18 ET (03:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6511","symbol_name":"医疗保健服务概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2613763105","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613763105","pubTimestamp":1771903080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0318 GMT - Raffles Medical Group is likely entering a stronger growth phase in 2026-2027, RHB Research's Shekhar Jaiswal says in a report. The recovery in its Singapore-based hospitals may extend on specialist-led volumes and supportive insurer-panel flow, while the losses at its China-based clinics could continue to narrow, the analyst says. The Singapore-listed healthcare provider's margins should also remain resilient on measured price increases and tech-driven productivity gains, offsetting wage inflation. RHB Research raises the stock's target price to S$1.30 from S$1.15 to reflect a valuation rollover, with its buy rating unchanged. Shares are 0.9% higher at S$1.08. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6511":"医疗保健服务概念","BK6092":"保健护理机构","BSL.SI":"莱佛士医疗"},"translate_title":"莱佛士医疗集团可能进入更强劲的增长阶段——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSL.SI":1.5},"content_text":"0318 GMT - Raffles Medical Group is likely entering a stronger growth phase in 2026-2027, RHB Research's Shekhar Jaiswal says in a report. The recovery in its Singapore-based hospitals may extend on specialist-led volumes and supportive insurer-panel flow, while the losses at its China-based clinics could continue to narrow, the analyst says. The Singapore-listed healthcare provider's margins should also remain resilient on measured price increases and tech-driven productivity gains, offsetting wage inflation. RHB Research raises the stock's target price to S$1.30 from S$1.15 to reflect a valuation rollover, with its buy rating unchanged. Shares are 0.9% higher at S$1.08. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 23, 2026 22:18 ET (03:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}